Last reviewed · How we verify
Monoclonal antibody BAT6026
At a glance
| Generic name | Monoclonal antibody BAT6026 |
|---|---|
| Also known as | BAT6026 |
| Sponsor | Bio-Thera Solutions |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety, Tolerability of BAT6026 (PHASE1, PHASE2)
- Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monoclonal antibody BAT6026 CI brief — competitive landscape report
- Monoclonal antibody BAT6026 updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI